BioSpace News Archive

The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.

Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market developments

At the Annual General Meeting in Recipharm AB on May 13, 2019, the shareholders adopted the resolutions summarized

Insys owes more than $240 million in legal-related fees but the company only has about $87 million in available cash.

The new incubator, located in Cambridge, Mass., launched with a $150 million Series A financing round.

Gilead’s Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that.

A systemically injectable peptide, which may make it possible to restore lost functions in spinal cord injury patients, is moving toward clinical trials in early 2020. It has seen success in animal models.

Antibe Therapeutics Chief Executive Officer Dan Legault likened developing an effective pain medication that is non-addictive and non-toxic to mountain climbers attempting to climb Mt. Everest.

Medtronic plc announced findings from a pilot study of its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver lifesaving defibrillation and anti-tachycardia pacing therapy in one system, with a device the same size as traditional, transvenous ICDs.

Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin